Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.53 |
| ▸ | NPC1 | O15118 | 10/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | ILK | Q13418 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29236215 | 0.87 | MEN1 (0.53) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL827403 | 0.81 | RAB9A (0.67) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL28477453 | 0.80 | MEN1 (0.53) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30494423 | 0.80 | MEN1 (0.53) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| Hydrogen Sulfide SCHEMBL16859912 | 0.79 | RAB9A (0.64) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL10009367 | 0.78 | KDM4E (0.52) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL10009918 | 0.78 | RAB9A (0.57) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1128092 | 0.78 | NPC1 (0.57) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| 2-Phenylbenzo[D]Thiazole SCHEMBL30988131 | 0.78 | RAB9A (0.75) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| 2-Phenylbenzo[D]Thiazole SCHEMBL94005 | 0.78 | RAB9A (0.75) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISIHARA YUJI | 2006-12-14 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-20040053826-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1331010-A1 | PREVENTIVES AND REMEDIES FOR CENTRAL NERVOUS SYSTEM DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| US-5620973-A | CHOLINESTERASE INHIBITOR; ALZHEIMER*S DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0655451-A1 | Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | RAB9A 1896/4885NPC1 2028/4885KDM4E 3540/4885 |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | RAB9A 763/4885NPC1 1992/4885KDM4E 562/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | RAB9A 1071/4885NPC1 1932/4885KDM4E 306/4885 |
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | RAB9A 1065/4885NPC1 1752/4885KDM4E 4438/4885 |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | RAB9A 812/4885NPC1 2214/4885KDM4E 460/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | RAB9A 2823/4885NPC1 2458/4885KDM4E 3707/4885 |
| US-20040053826-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | RAB9A 1065/4885NPC1 1752/4885KDM4E 4438/4885 |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | UTS2R, PRSS12, CTSA | RAB9A 3039/4885NPC1 469/4885KDM4E 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.